Self-assembled hydrogel nanoparticles from curdlan derivatives: characterization, anti-cancer drug release and interaction with a hepatoma cell line (HepG2).
Self-assembled hydrogel nanoparticles were synthesized from carboxymethylated (CM)-curdlan, substituted with a sulfonylurea (SU) as a hydrophobic moiety for self-assembly. The degree of SU substitution was 2.4, 5.6, or 7.2 SU groups per hundred anhydroglucose units of curdlan. The physicochemical properties of the self-assembled hydrogel nanoparticles (DS 2.4, DS 5.6, and DS 7.2) in aqueous media were characterized by dynamic light scattering, transmission electron microscopy, and fluorescence spectroscopy. The mean diameter of all samples was less than 300 nm with a unimodal size distribution. The critical aggregation concentrations (CAC) of self-assembled hydrogel nanoparticles in distilled water were 4.2 x 10(-2), 3.1 x 10(-2) and 1.9 x 10(-2) mg/ml for DS 2.4, 5.6 and 7.2, respectively. The loading and release of all-trans retinoic acid (ATRA) was studied. The ATRA loading efficiencies and loading contents of CM-curdlan/SU nanoparticles increased as the degree of SU substitution increased. The ATRA release rate was controlled by the degree of substitution and drug-loading. For specific interaction with a hepatic carcinoma cell line (HepG2), CM-curdlan was additionally conjugated with lactobionic acid (LBA; galactose moiety) (5.5 LBA molecules per hundred glucose units). HepG2 was strongly luminated by ligand-receptor interactions with fluorescence-labeled LBA/CM-curdlan/SU hydrogel nanoparticles. The luminescence was not observed for other control cases. It is concluded that LBA/CM-curdlan/SU hydrogel nanoparticles are a useful drug carrier for the treatment of liver cancer, because of the potential immunological enhancement activities of CM-curdlan in the body, the ligand-receptor mediated specific interactions, and the controlled release of the anti-cancer drug.
Na
K
K
Center for Biomaterial and Biotechnology, Department of Materials Science and Engineering, Kwangju Institute of Science and Technology, 1 Oryong-Dong, Puk-gu, Kwangju 500-712, South Korea.
Park
K H
KH
Kim
S W
SW
Bae
Y H
YH
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002240:Carbohydrate Sequence; D002478:Cells, Cultured; D003692:Delayed-Action Preparations; D005936:Glucans / Q000737:chemistry*; D020100:Hydrogels; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D018613:Microscopy, Confocal; D008854:Microscopy, Electron; D008863:Microspheres; D008969:Molecular Sequence Data; D011135:Polysaccharides, Bacterial / Q000737:chemistry*; D012542:Scattering, Radiation; D013050:Spectrometry, Fluorescence; D013453:Sulfonylurea Compounds / Q000737:chemistry; D014407:Tumor Cells, Cultured; D047071:beta-Glucans
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D005936:Glucans; D020100:Hydrogels; D011135:Polysaccharides, Bacterial; D013453:Sulfonylurea Compounds; D047071:beta-Glucans; C038459:curdlan